CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
阿扎胞苷联合维奈克拉与强化化疗治疗急性髓系白血病的安全性和有效性比较：一项倾向性评分匹配分析
英文原题：Comparative Safety and Effectiveness of Azacitidine plus Venetoclax versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score-Matched Analysis.
查看英文原题
Comparative Safety and Effectiveness of Azacitidine plus Venetoclax versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score-Matched Analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 60-75 岁的 AML 患者中，HMA&Ven 与 IC 相比，1 年全因死亡率相似，但安全性显著更优，中性粒细胞减少和脓毒症风险降低。
研究思路结论见上方概要
背景
阿扎胞苷联合维奈克拉（HMA&Ven）因其良好的疗效和安全性，已成为老年或医学上不适合的急性髓系白血病（AML）患者的确立治疗方法。近年来，人们越来越关注将其应用扩展至传统上接受强化化疗（IC）的较年轻、较适合的患者。然而，此前比较HMA&Ven与IC的研究受限于样本量小和结果不确定。
方法
我们利用TriNetX数据库开展了一项倾向性评分匹配队列研究，旨在比较该人群中HMA&Ven与IC的死亡率和安全性结局。我们纳入了年龄60-75岁、诊断为AML并接受HMA&Ven或IC作为诱导治疗的患者。诱导治疗后接受骨髓移植或CAR-T 细胞治疗的患者被排除。我们根据预先确定的变量对患者进行匹配，如年龄、性别、种族、合并症、用药、社会经济状况和医疗资源利用情况。
结果
最终分析每组纳入370例患者。在1年随访时，HMA&Ven的全因死亡率与IC相当（HR：1.16 [95% CI：0.93-1.44]，p值=0.186）。然而，HMA&Ven与显著更低的中性粒细胞减少症发生率（HR：0.72 [95% CI：0.60-0.87]，p值<0.001）和脓毒症发生率（HR：0.72 [95% CI：0.56-0.92]，p值=0.009）相关。
展开英文摘要原文
METHODS
We conducted a propensity score-matched cohort study using the TriNetX database to compare mortality and safety outcomes between HMA&Ven and IC in this population. We included patients aged 60-75 years with a diagnosis of AML who received either HMA&Ven or IC as induction therapy. Patients who underwent bone marrow transplantation or chimeric antigen receptor T-cell therapy following induction were excluded. We matched patients on predetermined variables, such as age, sex, race, comorbidities, medication, socioeconomic status, and healthcare utilization.
RESULTS
The final analysis included 370 patients in each treatment group. At the 1-year follow-up, HMA&Ven demonstrated comparable all-cause mortality to IC (HR: 1.16 [95% CI: 0.93-1.44], p value = 0.186). However, HMA&Ven was associated with significantly lower rates of neutropenia (HR: 0.72 [95% CI: 0.60-0.87], p value <0.001) and sepsis (HR: 0.72 [95% CI: 0.56-0.92], p value = 0.009).
CONCLUSION
Among AML patients aged 60-75, HMA&Ven showed similar 1-year all-cause mortality compared to IC, while offering a significantly better safety profile with reduced risks of neutropenia and sepsis.
论文信息
- 作者
- Chang YC、Lin HK、Lee YC、Chiang CH、Gao W
- 单位
- Department of Medicine, Danbury Hospital, Danbury, Connecticut, USA, yucheng.chang@nuvancehealth.org.United States
- 文献类型
- 对照研究
- 期刊
- Oncology2026
- 原文标识
- PubMed 40675138 · DOI 10.1159/000547415